{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:16:24Z","timestamp":1793038584291,"version":"4.5.0"},"reference-count":306,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-vitamin K oral anticoagulants (NOACs) have revolutionized anticoagulant therapy, offering improved safety and efficacy over traditional agents like warfarin. This review comprehensively examines the dual roles of NOACs\u2014apixaban, rivaroxaban, edoxaban, and dabigatran\u2014not only as anticoagulants, but also as modulators of inflammation via protease-activated receptor (PAR) signaling. We highlight the unique pharmacotherapeutic properties of each NOAC, supported by key clinical trials demonstrating their effectiveness in preventing thromboembolic events. Beyond their established anticoagulant roles, emerging research suggests that NOACs influence inflammation through PAR signaling pathways, implicating factors such as factor Xa (FXa) and thrombin in the modulation of inflammatory responses. This review synthesizes current evidence on the anti-inflammatory potential of NOACs, exploring their impact on inflammatory markers and conditions like atherosclerosis and diabetes. By delineating the mechanisms by which NOACs mediate anti-inflammatory effects, this work aims to expand their therapeutic utility, offering new perspectives for managing inflammatory diseases. Our findings underscore the broader clinical implications of NOACs, advocating for their consideration in therapeutic strategies aimed at addressing inflammation-related pathologies. This comprehensive synthesis not only enhances understanding of NOACs\u2019 multifaceted roles, but also paves the way for future research and clinical applications in inflammation and cardiovascular health.<\/jats:p>","DOI":"10.3390\/ijms25168727","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T03:46:36Z","timestamp":1723607196000},"page":"8727","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling"],"prefix":"10.3390","volume":"25","author":[{"given":"Shirin","family":"Jannati","sequence":"first","affiliation":[{"name":"Yajnavalkaa Banerrji Research Group, College of Medicine and Health Sciences, Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai P.O. Box 505055, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-7007","authenticated-orcid":false,"given":"Rajashree","family":"Patnaik","sequence":"additional","affiliation":[{"name":"Yajnavalkaa Banerrji Research Group, College of Medicine and Health Sciences, Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai P.O. Box 505055, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-8893","authenticated-orcid":false,"given":"Yajnavalka","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Yajnavalkaa Banerrji Research Group, College of Medicine and Health Sciences, Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Dubai Health, Dubai P.O. Box 505055, United Arab Emirates"},{"name":"Centre for Medical Education, University of Dundee, Dundee DD1 4HN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J. Anaesth."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3324\/haematol.2020.248542","article-title":"Biochemical, molecular and clinical aspects of coagulation factor VII and its role in hemostasis and thrombosis","volume":"106","author":"Bernardi","year":"2021","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1160\/TH09-11-0771","article-title":"Tissue factor and thrombosis: The clot starts here","volume":"104","author":"Owens","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"ref_5","unstructured":"England, N.H.S.N. (2024, June 15). Community Pharmacy Oral Anticoagulant Safety Audit 2021\/22: NHS England. Available online: https:\/\/www.england.nhs.uk\/long-read\/community-pharmacy-oral-anticoagulant-safety-audit-2021-22\/#about-this-report."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trsl.2020.04.014","article-title":"Pathogenesis of heparin-induced thrombocytopenia","volume":"225","author":"Arepally","year":"2020","journal-title":"Transl. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1517\/14656566.9.5.677","article-title":"Warfarin therapy: In need of improvement after all these years","volume":"9","author":"Kimmel","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Shields, L.B.E., Fowler, P., Siemens, D.M., Lorenz, D.J., Wilson, K.C., Hester, S.T., and Honaker, J.T. (2019). Standardized warfarin monitoring decreases adverse drug reactions. BMC Fam. Pract., 20.","DOI":"10.1186\/s12875-019-1041-5"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bcp.14404","article-title":"Warfarin and food, herbal or dietary supplement interactions: A systematic review","volume":"87","author":"Tan","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11239-024-02951-w","article-title":"A systematic review of therapeutic enoxaparin dosing in obesity","volume":"57","author":"Chilbert","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/a-1606-7523","article-title":"Non-Vitamin K Antagonist Oral Anticoagulants in Coronary Artery Disease","volume":"42","author":"Ellscheid","year":"2022","journal-title":"Hamostaseologie"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00108-017-0243-y","article-title":"Anticoagulation-direct oral anticoagulants","volume":"58","year":"2017","journal-title":"Internist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants: Pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00228-017-2374-4","article-title":"Prescribing of NOACs has outnumbered warfarin: Exploring how physicians choose anticoagulant treatments","volume":"74","author":"Eek","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: Food, herbal medicines and drug interactions","volume":"31","author":"Frigerio","year":"2017","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"117S","DOI":"10.1177\/1076029618796339","article-title":"The Reversal of Bleeding Caused by New Oral Anticoagulants (NOACs): A Systematic Review and Meta-Analysis","volume":"24","author":"Udayachalerm","year":"2018","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/ATVBAHA.117.306995","article-title":"Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective","volume":"37","author":"Hoffman","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of Bleeding with Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI17564","article-title":"PARticipation in inflammation","volume":"111","author":"Coughlin","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/jth.15289","article-title":"Off-target effects of oral anticoagulants\u2014Vascular effects of vitamin K antagonist and non-vitamin K antagonist oral anticoagulant dabigatran etexilate","volume":"19","author":"Dijkgraaf","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jacbts.2021.09.010","article-title":"Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa-PAR2-Mediated Autophagy Suppression","volume":"6","author":"Ito","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1021\/jm200868m","article-title":"Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor","volume":"54","author":"Hirayama","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lagos, C.F., Segovia, G.F., Nunez-Navarro, N., Faundez, M.A., and Zacconi, F.C. (2017). Novel FXa Inhibitor Identification through Integration of Ligand- and Structure-Based Approaches. Molecules, 22.","DOI":"10.3390\/molecules22101588"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0006-291X(68)90326-4","article-title":"On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain","volume":"32","author":"Schechter","year":"1968","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1538-7836.2008.02939.x","article-title":"Apixaban, an oral, direct and highly selective factor Xa inhibitor: In vitro, antithrombotic and antihemostatic studies","volume":"6","author":"Wong","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1538-7836.2004.01021.x","article-title":"Exosite-driven substrate specificity and function in coagulation","volume":"3","author":"Krishnaswamy","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014An oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1111\/j.1538-7836.2008.03064.x","article-title":"DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles","volume":"6","author":"Furugohri","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/eurheartj\/ehu181","article-title":"Edoxaban: A focused review of its clinical pharmacology","volume":"35","author":"Lip","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.02.028","article-title":"Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux","volume":"141","author":"Honda","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-2007-998998","article-title":"Molecular Interactions of Thrombin","volume":"22","author":"Tulinsky","year":"1996","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_36","first-page":"27F","article-title":"The mechanism of action of thrombin inhibitors","volume":"12","author":"Bates","year":"2000","journal-title":"J. Invasive Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1160\/TH07-03-0183","article-title":"In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate","volume":"98","author":"Wienen","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: An oral novel potent reversible nonpeptide inhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","article-title":"Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa","volume":"16","author":"Vakkalagadda","year":"2016","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcph.540","article-title":"Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule","volume":"55","author":"Parasrampuria","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cpdd.53","article-title":"Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects","volume":"2","author":"Matsushima","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/bjh.17004","article-title":"Evidence of impaired dabigatran absorption following laparoscopic Roux-en-Y gastric bypass surgery: The Auckland regional experience (2011\u20132018)","volume":"191","author":"Grainger","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003088-200847010-00005","article-title":"Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1124\/dmd.112.050260","article-title":"Characterization of efflux transporters involved in distribution and disposition of apixaban","volume":"41","author":"Zhang","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00228-014-1736-4","article-title":"Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation","volume":"70","author":"Yin","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","first-page":"e5484","article-title":"Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects","volume":"11","author":"Bratsos","year":"2019","journal-title":"Cureus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/0091270010370974","article-title":"Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers","volume":"51","author":"Mendell","year":"2011","journal-title":"J. Clin. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"549","DOI":"10.5414\/CP201812","article-title":"The effect of food on the absorption and pharmacokinetics of rivaroxaban","volume":"51","author":"Stampfuss","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","article-title":"Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban","volume":"54","author":"Frost","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jcph.5","article-title":"The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban\u2014An oral, direct Factor Xa inhibitor","volume":"53","author":"Kubitza","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/psp4.12184","article-title":"Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism","volume":"6","author":"Byon","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_59","unstructured":"Sankyo, D. (2020). Lixiana Summary of Product Characteristics, European Medicine Agency."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12959-015-0067-8","article-title":"Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: Pooled analysis of two phase 3 randomized trials","volume":"13","author":"Eriksson","year":"2015","journal-title":"Thromb. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus Warfarin for Acute Venous Thromboembolism in Elderly or Impaired Renal Function Patients: Pooled Analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Diez-Villanueva, P., Cosin-Sales, J., Roldan-Schilling, V., Barrios, V., Riba-Artes, D., Gavin-Sebastian, O., and RE_BELD Spanish Investigator\u2019s Group (2023). Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain. J. Clin. Med., 12.","DOI":"10.3390\/jcm12031224"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e12841","DOI":"10.1097\/MD.0000000000012841","article-title":"Comparison of dabigatran and warfarin used in patients with non-valvular atrial fibrillation: Meta-analysis of random control trial","volume":"97","author":"Yu","year":"2018","journal-title":"Medicine"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Grymonprez, M., De Backer, T.L., Bertels, X., Steurbaut, S., and Lahousse, L. (2023). Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1125576"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jth.13595","article-title":"Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation","volume":"15","author":"Achilles","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"762310","DOI":"10.1155\/2013\/762310","article-title":"The efficacy and safety of rivaroxaban for venous thromboembolism prophylaxis after total hip and total knee arthroplasty","volume":"2013","author":"Russell","year":"2013","journal-title":"Thrombosis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: A pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/CIRCULATIONAHA.123.063901","article-title":"Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients with COVID-19: A Randomized Clinical Trial","volume":"147","author":"Piazza","year":"2023","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of Rivaroxaban vs Apixaban with Major Ischemic or Hemorrhagic Events in Patients with Atrial Fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e072623","DOI":"10.1136\/bmj-2022-072623","article-title":"Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: Randomised controlled trial","volume":"379","author":"Ageno","year":"2022","journal-title":"BMJ"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8886210","DOI":"10.1155\/2021\/8886210","article-title":"Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review","volume":"2021","author":"Ajmal","year":"2021","journal-title":"Cardiovasc. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cohen, A.T., Wallenhorst, C., Rivera, M., Ay, C., Schaefer, B., Abdelgawwad, K., Psaroudakis, G., Brobert, G., Ekbom, A., and Lee, A.Y.Y. (2024). Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study. Thromb. Haemost.","DOI":"10.1055\/a-2259-0662"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e2044","DOI":"10.1002\/hsr2.2044","article-title":"Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: A systematic review and meta-analysis","volume":"7","author":"Adelkhanova","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): A randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e002340","DOI":"10.1161\/JAHA.115.002340","article-title":"Apixaban Reduces Hospitalizations in Patients with Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial","volume":"4","author":"Liu","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2016.03.019","article-title":"Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study","volume":"178","author":"Eikelboom","year":"2016","journal-title":"Am. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial","volume":"3","author":"Guntupalli","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A Randomized Controlled Trial Comparing Apixaban with the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for Prevention of Thromboembolism in Pediatric Heart Disease","volume":"82","author":"Payne","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/S2352-3026(23)00314-9","article-title":"Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): A phase 3, open-label, randomised, controlled trial","volume":"11","author":"Rodriguez","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Hokusai","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: Results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.thromres.2014.03.009","article-title":"Safety and efficacy of edoxaban in patients undergoing hip fracture surgery","volume":"133","author":"Fuji","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.thromres.2014.09.011","article-title":"Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The STARS E-3 trial","volume":"134","author":"Fuji","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1253\/circj.CJ-14-0942","article-title":"Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients with Non-Valvular Atrial Fibrillation and Severe Renal Impairment","volume":"79","author":"Koretsune","year":"2015","journal-title":"Circ. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for Thromboembolism Prevention in Pediatric Patients with Cardiac Disease","volume":"80","author":"Portman","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtcvs.2021.01.127","article-title":"Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial","volume":"165","author":"Shim","year":"2023","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","article-title":"A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients with Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial","volume":"149","author":"Hosokawa","year":"2024","journal-title":"Circulation"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1038\/sj.bjp.0707507","article-title":"Proteinases and signalling: Pathophysiological and therapeutic implications via PARs and more","volume":"153","author":"Ramachandran","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/29325","article-title":"A dual thrombin receptor system for platelet activation","volume":"394","author":"Kahn","year":"1998","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1124\/pr.111.004747","article-title":"Cofactoring and dimerization of proteinase-activated receptors","volume":"65","author":"Lin","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11239-021-02458-8","article-title":"Roles of factor Xa beyond coagulation","volume":"52","author":"Ruf","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2013.09.006","article-title":"Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue","volume":"718","author":"Bukowska","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"ref_109","first-page":"1505","article-title":"Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor","volume":"23","author":"Ohba","year":"1996","journal-title":"J. Rheumatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1007\/s12031-015-0512-y","article-title":"Thrombin Activity and Thrombin Receptor in Rat Glioblastoma Model: Possible Markers and Targets for Intervention?","volume":"56","author":"Last","year":"2015","journal-title":"J. Mol. Neurosci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-0502(03)00045-4","article-title":"Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin","volume":"28","author":"Ofosu","year":"2003","journal-title":"Transfus. Apher. Sci."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1073\/pnas.96.20.11023","article-title":"How the protease thrombin talks to cells","volume":"96","author":"Coughlin","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1007\/s11064-015-1711-1","article-title":"Concentration-Dependent Dual Role of Thrombin in Protection of Cultured Rat Cortical Neurons","volume":"40","author":"Garcia","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12974-017-0901-y","article-title":"Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1beta","volume":"14","author":"Lee","year":"2017","journal-title":"J. Neuroinflamm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3233\/JAD-180786","article-title":"Glia Maturation Factor and Mast Cell-Dependent Expression of Inflammatory Mediators and Proteinase Activated Receptor-2 in Neuroinflammation","volume":"66","author":"Kempuraj","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Takayama, Y., Derouiche, S., Maruyama, K., and Tominaga, M. (2019). Emerging Perspectives on Pain Management by Modulation of TRP Channels and ANO1. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143411"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1074\/jbc.M112.438184","article-title":"Protease-activated receptor 2 (PAR2) protein and transient receptor potential vanilloid 4 (TRPV4) protein coupling is required for sustained inflammatory signaling","volume":"288","author":"Poole","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1172\/JCI29255","article-title":"Role for protease activity in visceral pain in irritable bowel syndrome","volume":"117","author":"Cenac","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/89945","article-title":"Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway","volume":"7","author":"Vergnolle","year":"2001","journal-title":"Nat. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/sj.bjp.0704568","article-title":"Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli","volume":"135","author":"Asfaha","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/MIB.0000000000001045","article-title":"Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity","volume":"23","author":"Saeed","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/01.mib.0000177506.71784.bd","article-title":"Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response","volume":"11","author":"Cenac","year":"2005","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/jth.14641","article-title":"Cell type-specific mechanisms coupling protease-activated receptor-1 to infectious colitis pathogenesis","volume":"18","author":"Boucher","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"C113","DOI":"10.1152\/ajpcell.00162.2010","article-title":"Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium","volume":"300","author":"Lau","year":"2011","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1073\/pnas.0409535102","article-title":"A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis","volume":"102","author":"Hansen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ibd\/izaa125","article-title":"Mast Cell Tryptase Promotes Inflammatory Bowel Disease-Induced Intestinal Fibrosis","volume":"27","author":"Liu","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"G30","DOI":"10.1152\/ajpgi.00203.2020","article-title":"Blockage of protease-activated receptor 2 exacerbates inflammation in high-fat environment partly through autophagy inhibition","volume":"320","author":"Her","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"00489","DOI":"10.1183\/23120541.00489-2020","article-title":"Proteomic profiling of peripheral blood and bronchoalveolar lavage fluid in interstitial lung diseases: An explorative study","volume":"7","author":"Majewski","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"7464","DOI":"10.1038\/s41598-017-07791-8","article-title":"Bronchoalveolar Lavage Fluid Protein Expression in Acute Respiratory Distress Syndrome Provides Insights into Pathways Activated in Subjects with Different Outcomes","volume":"7","author":"Bhargava","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMcibr1311045","article-title":"Asthma and coagulation","volume":"369","author":"Lambrecht","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1182\/blood-2011-11-391532","article-title":"Asthma and coagulation","volume":"119","author":"Majoor","year":"2012","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"8179","DOI":"10.1111\/jcmm.15485","article-title":"Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes-associated protein","volume":"24","author":"Deng","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yue, M., Hu, M., Fu, F., Ruan, H., and Wu, C. (2022). Emerging Roles of Platelets in Allergic Asthma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.846055"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Gandhi, V.D., Shrestha Palikhe, N., and Vliagoftis, H. (2022). Protease-activated receptor-2: Role in asthma pathogenesis and utility as a biomarker of disease severity. Front. Med., 9.","DOI":"10.3389\/fmed.2022.954990"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"230126","DOI":"10.1183\/16000617.0126-2023","article-title":"Airborne indoor allergen serine proteases and their contribution to sensitisation and activation of innate immunity in allergic airway disease","volume":"33","author":"Ouyang","year":"2024","journal-title":"Eur. Respir. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/bph.15745","article-title":"Proteinase-activated receptor-2 antagonist C391 inhibits Alternaria-induced airway epithelial signalling and asthma indicators in acute exposure mouse models","volume":"179","author":"Rivas","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1164\/ajrccm.161.5.9907133","article-title":"Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways","volume":"161","author":"Ricciardolo","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1164\/ajrccm.162.5.9912099","article-title":"Trypsin-induced, neurokinin-mediated contraction of guinea pig bronchus","volume":"162","author":"Carr","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1164\/ajrccm.164.7.2101157","article-title":"Expression and function of proteinase-activated receptor 2 in human bronchial smooth muscle","volume":"164","author":"Schmidlin","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_140","first-page":"L22","article-title":"alpha-Thrombin stimulates contraction of human bronchial rings by activation of protease-activated receptors","volume":"277","author":"Hauck","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/jcmm.12520","article-title":"Protease-activated receptor (PAR)-2 is required for PAR-1 signalling in pulmonary fibrosis","volume":"19","author":"Lin","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1042\/bst0300211","article-title":"Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis","volume":"30","author":"Howell","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"576","DOI":"10.2119\/molmed.2015.00094","article-title":"Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis","volume":"21","author":"Lin","year":"2015","journal-title":"Mol. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1111\/jth.12392","article-title":"Dose-dependent differential effects of thrombin in allergic bronchial asthma","volume":"11","author":"Miyake","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.4049\/jimmunol.1500124","article-title":"Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection","volume":"194","author":"Jose","year":"2015","journal-title":"J. Immunol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0140-6736(15)60367-1","article-title":"Regulation of neutrophilic inflammation in lung injury induced by community-acquired pneumonia","volume":"385","author":"Jose","year":"2015","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/infdis\/jiy010","article-title":"Protease-Activated Receptor 2 Facilitates Bacterial Dissemination in Pneumococcal Pneumonia","volume":"217","author":"Brands","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.celrep.2019.03.053","article-title":"PAR2-Mediated cAMP Generation Suppresses TRPV4-Dependent Ca(2+) Signaling in Alveolar Macrophages to Resolve TLR4-Induced Inflammation","volume":"27","author":"Rayees","year":"2019","journal-title":"Cell Rep."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1160\/TH13-01-0052","article-title":"Protease activated receptor 4 limits bacterial growth and lung pathology during late stage Streptococcus pneumoniae induced pneumonia in mice","volume":"110","author":"Nieuwland","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1161\/01.RES.86.10.1054","article-title":"Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors","volume":"86","author":"Sabri","year":"2000","journal-title":"Circ. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s10517-007-0425-z","article-title":"Proteinase-activated receptor agonists stimulate the increase in intracellular Ca2+ in cardiomyocytes and proliferation of cardiac fibroblasts from chick embryos","volume":"144","author":"Ide","year":"2007","journal-title":"Bull. Exp. Biol. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.107.692764","article-title":"Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy","volume":"116","author":"Pawlinski","year":"2007","journal-title":"Circulation"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"472","DOI":"10.2174\/1381612822666151222160933","article-title":"The Role of Protease-Activated Receptors for the Development of Myocarditis: Possible Therapeutic Implications","volume":"22","author":"Weithauser","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI66125","article-title":"PAR-1 contributes to the innate immune response during viral infection","volume":"123","author":"Antoniak","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"103949","DOI":"10.1016\/j.cellimm.2019.103949","article-title":"Protease-activated receptor 4 protects mice from Coxsackievirus B3 and H1N1 influenza A virus infection","volume":"344","author":"Tatsumi","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/cimm.1996.0212","article-title":"Thrombin modulation of natural killer activity in human peripheral lymphocytes","volume":"172","author":"Naldini","year":"1996","journal-title":"Cell. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.thromres.2014.03.011","article-title":"Roles of PAR1 and PAR2 in viral myocarditis","volume":"133","author":"Mackman","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2152\/jmi.58.19","article-title":"Effects of inhibitors of Toll-like receptors, protease-activated receptor-2 signalings and trypsin on influenza A virus replication and upregulation of cellular factors in cardiomyocytes","volume":"58","author":"Pan","year":"2011","journal-title":"J. Med. Investig."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Kouzoukas, D.E., Meyer-Siegler, K.L., Ma, F., Westlund, K.N., Hunt, D.E., and Vera, P.L. (2015). Macrophage Migration Inhibitory Factor Mediates PAR-Induced Bladder Pain. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127628"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/iju.13778","article-title":"Protease activated-receptor 4 activation as a model of persistent bladder pain: Essential role of macrophage migration inhibitory factor and high mobility group box 1","volume":"25","author":"Ma","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Saban, R., D\u2019Andrea, M.R., Andrade-Gordon, P., Derian, C.K., Dozmorov, I., Ihnat, M.A., Hurst, R.E., Davis, C.A., Simpson, C., and Saban, M.R. (2007). Mandatory role of proteinase-activated receptor 1 in experimental bladder inflammation. BMC Physiol., 7.","DOI":"10.1186\/1472-6793-7-3"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/bph.13501","article-title":"F16357, a novel protease-activated receptor 1 antagonist, improves urodynamic parameters in a rat model of interstitial cystitis","volume":"173","author":"Monjotin","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"R1127","DOI":"10.1152\/ajpregu.00310.2009","article-title":"Role of mast cells and protease-activated receptor-2 in cyclooxygenase-2 expression in urothelial cells","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nrneph.2015.177","article-title":"The emerging role of coagulation proteases in kidney disease","volume":"12","author":"Madhusudhan","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.yexcr.2004.10.021","article-title":"Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation","volume":"304","author":"Archer","year":"2005","journal-title":"Exp. Cell Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"10858","DOI":"10.1038\/s41598-018-29008-2","article-title":"Renoprotective effects of a factor Xa inhibitor: Fusion of basic research and a database analysis","volume":"8","author":"Horinouchi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/1440-1681.13077","article-title":"Pharmacological inhibition of protease-activated receptor-2 reduces crescent formation in rat nephrotoxic serum nephritis","volume":"46","author":"Han","year":"2019","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1172\/JCI16913","article-title":"Essential role for proteinase-activated receptor-2 in arthritis","volume":"111","author":"Ferrell","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/art.22423","article-title":"Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: Ex vivo studies using a novel proteinase-activated receptor 2 antagonist","volume":"56","author":"Kelso","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1476-5381.2012.02120.x","article-title":"Activation of PAR(2) receptors sensitizes primary afferents and causes leukocyte rolling and adherence in the rat knee joint","volume":"167","author":"Russell","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10067-006-0495-8","article-title":"Distinct expression of mast cell tryptase and protease activated receptor-2 in synovia of rheumatoid arthritis and osteoarthritis","volume":"26","author":"Nakano","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1002\/art.22936","article-title":"Protease-activated receptor 2 mediates the proinflammatory effects of synovial mast cells","volume":"56","author":"Palmer","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/annrheumdis-2011-200703","article-title":"PAR(2) expression in peripheral blood monocytes of patients with rheumatoid arthritis","volume":"71","author":"Crilly","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1124\/jpet.105.093807","article-title":"Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation","volume":"316","author":"Kelso","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7150\/ijbs.12690","article-title":"uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin\/PAR-1\/Ca(2+)\/CaMKK\/AMPK Axis","volume":"12","author":"Kanno","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/art.34557","article-title":"Thrombin induces epidermal growth factor receptor transactivation and CCL2 expression in human osteoblasts","volume":"64","author":"Huang","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.61.9.834","article-title":"Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts","volume":"61","author":"Hirano","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1254\/jphs.08126FP","article-title":"Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1","volume":"108","author":"Furuhashi","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/art.33323","article-title":"Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis","volume":"64","author":"Xue","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Patnaik, R., Riaz, S., Sivani, B.M., Faisal, S., Naidoo, N., Rizzo, M., and Banerjee, Y. (2023). Evaluating the potential of Vitamin D and curcumin to alleviate inflammation and mitigate the progression of osteoarthritis through their effects on human chondrocytes: A proof-of-concept investigation. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0290739"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/heartjnl-2015-308887","article-title":"Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation","volume":"102","author":"Hijazi","year":"2016","journal-title":"Heart"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1161\/CIRCULATIONAHA.114.011204","article-title":"Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"130","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"e000908","DOI":"10.1136\/openhrt-2018-000908","article-title":"Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: Insights from the ARISTOTLE trial","volume":"5","author":"Sandhu","year":"2018","journal-title":"Open Heart"},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Golderman, V., Gofrit, S.G., Maggio, N., Gera, O., Gerasimov, A., Laks, D., Chapman, J., and Shavit-Stein, E. (2020). A Novel Highly Sensitive Method for Measuring Inflammatory Neural-Derived APC Activity in Glial Cell Lines, Mouse Brain and Human CSF. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21072422"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1097\/CCM.0000000000004286","article-title":"Multi-Modal Characterization of the Coagulopathy Associated with Extracorporeal Membrane Oxygenation","volume":"48","author":"Granja","year":"2020","journal-title":"Crit. Care Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10557-020-07010-z","article-title":"Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia","volume":"35","author":"Palomo","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"12732","DOI":"10.1038\/s41598-023-39907-8","article-title":"IL-1beta transgenic mouse model of inflammation driven esophageal and oral squamous cell carcinoma","volume":"13","author":"Muthupalani","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e42964","DOI":"10.2196\/42964","article-title":"Efficient Generation of Chondrocytes From Bone Marrow-Derived Mesenchymal Stem Cells in a 3D Culture System: Protocol for a Practical Model for Assessing Anti-Inflammatory Therapies","volume":"12","author":"Patnaik","year":"2023","journal-title":"JMIR Res. Protoc."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Suarez-Martinez, E., Suazo-Sanchez, I., Celis-Romero, M., and Carnero, A. (2022). 3D and organoid culture in research: Physiology, hereditary genetic diseases and cancer. Cell Biosci., 12.","DOI":"10.1186\/s13578-022-00775-w"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"20384","DOI":"10.1038\/s41598-020-77348-9","article-title":"Author Correction: Multicellular 3D Neurovascular Unit Model for Assessing Hypoxia and Neuroinflammation Induced Blood-Brain Barrier Dysfunction","volume":"10","author":"Nzou","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2180373","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"7403796","DOI":"10.1155\/2019\/7403796","article-title":"Regulation of Inflammation in Autoimmune Disease","volume":"2019","author":"Duan","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Zhu, Q., Wu, Y., Mai, J., Guo, G., Meng, J., Fang, X., Chen, X., Liu, C., and Zhong, S. (2022). Comprehensive Metabolic Profiling of Inflammation Indicated Key Roles of Glycerophospholipid and Arginine Metabolism in Coronary Artery Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.829425"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1161\/ATVBAHA.116.307883","article-title":"Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy","volume":"36","author":"Oe","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Bieber, M., Foerster, K.I., Haefeli, W.E., Pham, M., Schuhmann, M.K., and Kraft, P. (2021). Treatment with Edoxaban Attenuates Acute Stroke Severity in Mice by Reducing Blood-Brain Barrier Damage and Inflammation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22189893"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"106661","DOI":"10.1016\/j.vph.2020.106661","article-title":"Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth","volume":"127","author":"Millenaar","year":"2020","journal-title":"Vasc. Pharmacol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11239-021-02381-y","article-title":"Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats","volume":"52","author":"Morishima","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"ofaa026","DOI":"10.1093\/ofid\/ofaa026","article-title":"Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People with HIV: A Randomized Clinical Trial","volume":"7","author":"Baker","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00399-023-00944-5","article-title":"Pleiotropic effects of NOACs with focus on edoxaban: Scientific findings and potential clinical implications","volume":"34","author":"Goette","year":"2023","journal-title":"Herzschrittmacherther. Elektrophysiol."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Narita, Y., Hamamura, K., Kashiyama, M., Utsumi, S., Kakizoe, Y., Kondo, Y., Ishitsuka, Y., Jono, H., Irie, T., and Mukoyama, M. (2019). Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174140"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijcard.2023.05.031","article-title":"Neutrophil-lymphocyte ratio and clinical outcomes in 19,697 patients with atrial fibrillation: Analyses from ENGAGE AF- TIMI 48 trial","volume":"386","author":"Fagundes","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Romero-Guevara, R., Ioannides, A., and Xinaris, C. (2020). Kidney Organoids as Disease Models: Strengths, Weaknesses and Perspectives. Front. Physiol., 11.","DOI":"10.3389\/fphys.2020.563981"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1160\/TH12-05-0310","article-title":"Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor","volume":"108","author":"Chan","year":"2012","journal-title":"Thromb. Haemost."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/bcp.13383","article-title":"FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms","volume":"83","author":"Monux","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/07853890.2018.1495337","article-title":"Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: Biomarker substudy results from a prospective study with rivaroxaban (X-TRA)","volume":"50","author":"Miyazawa","year":"2018","journal-title":"Ann. Med."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Martins, G.L., Duarte, R.C.F., Vieira, E.L.M., Rocha, N.P., Figueiredo, E.L., Silveira, F.R., Caiaffa, J.R.S., Lanna, R.P., Carvalho, M.D.G., and Palotas, A. (2020). Comparison of Inflammatory Mediators in Patients with Atrial Fibrillation Using Warfarin or Rivaroxaban. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00114"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s12012-019-09551-8","article-title":"Protective Effect of RIVA Against Sunitinib-Induced Cardiotoxicity by Inhibiting Oxidative Stress-Mediated Inflammation: Probable Role of TGF-beta and Smad Signaling","volume":"20","author":"Imam","year":"2020","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial","volume":"4","author":"Kirchhof","year":"2020","journal-title":"TH Open."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s00125-021-05562-9","article-title":"Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: A randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers","volume":"64","author":"Pistrosch","year":"2021","journal-title":"Diabetologia"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijcard.2021.10.025","article-title":"New evidence of direct oral anticoagulation therapy on cardiac valve calcifications, renal preservation and inflammatory modulation","volume":"345","author":"Lavalle","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1111\/jth.15434","article-title":"Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro-inflammatory protein signatures","volume":"19","author":"Weiss","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/clc.23833","article-title":"Significant decrease in plasmad-dimer levels and mean platelet volume after a 3-month treatment with rosuvastatin in patients with venous thromboembolism","volume":"45","author":"Alirezaei","year":"2022","journal-title":"Clin. Cardiol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/FJC.0000000000001382","article-title":"Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis","volume":"81","author":"Russo","year":"2023","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.thromres.2013.11.013","article-title":"Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus","volume":"133","author":"Iba","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2162-3619-3-30","article-title":"Comparative study of the effect of rivaroxaban and fondaparinux on monocyte\u2019s coagulant activity and cytokine release","volume":"3","author":"Laurent","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.atherosclerosis.2015.03.023","article-title":"Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice","volume":"242","author":"Hara","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"35580","DOI":"10.1038\/srep35580","article-title":"Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5","volume":"6","author":"Sanada","year":"2016","journal-title":"Sci Rep."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2016.06.008","article-title":"Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis","volume":"144","author":"Terry","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1160\/TH15-08-0631","article-title":"Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism","volume":"115","author":"Dittmeier","year":"2016","journal-title":"Thromb. Haemost."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12974-017-0926-2","article-title":"Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis","volume":"14","author":"Stolz","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jphs.2017.02.010","article-title":"Demeanor of rivaroxaban in activated\/inactivated FXa","volume":"133","author":"Seki","year":"2017","journal-title":"J. Pharmacol. Sci."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"17172","DOI":"10.1038\/s41598-017-17508-6","article-title":"Local Production of Activated Factor X in Atherosclerotic Plaque Induced Vascular Smooth Muscle Cell Senescence","volume":"7","author":"Sanada","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_223","first-page":"2335","article-title":"Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2\/NF-kappaB signaling pathway","volume":"10","author":"Shi","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2017.12.037","article-title":"Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury","volume":"820","author":"Hara","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jjcc.2017.08.007","article-title":"Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation","volume":"71","author":"Kondo","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.thromres.2018.05.015","article-title":"The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction","volume":"167","author":"Bode","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Mahmoud, N.I., Messiha, B.A.S., Abo-Saif, A.A., and Abdel-Bakky, M.S. (2019). Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats. J Biochem. Mol. Toxicol., 33.","DOI":"10.1002\/jbt.22287"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"915","DOI":"10.5551\/jat.48405","article-title":"Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction","volume":"26","author":"Liu","year":"2019","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1253\/circrep.CR-19-0117","article-title":"Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice","volume":"2","author":"Nakanishi","year":"2020","journal-title":"Circ. Rep."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11239-020-02123-6","article-title":"Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-alpha induced nuclear factor-kappaappa B signaling pathway in rats","volume":"50","author":"Imam","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Daci, A., Da Dalt, L., Alaj, R., Shurdhiqi, S., Neziri, B., Ferizi, R., Norata, G.D., and Krasniqi, S. (2020). Rivaroxaban improves vascular response in LPS-induced acute inflammation in experimental models. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0240669"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1111\/jth.15075","article-title":"Effect of myeloperoxidase on the anticoagulant activity of low molecular weight heparin and rivaroxaban in an in vitro tumor model","volume":"18","author":"Voigtlaender","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"106818","DOI":"10.1016\/j.vph.2020.106818","article-title":"Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation","volume":"136","author":"Ding","year":"2021","journal-title":"Vascul. Pharmacol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0041-1729468","article-title":"Effects of Routine Antithrombotic-Adjusted Dose of Rivaroxaban and Nadroparin Calcium on Tendon Healing of Rats: An Experimental Study","volume":"15","author":"Altun","year":"2023","journal-title":"J. Hand Microsurg."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1253\/circj.CJ-20-1006","article-title":"Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation","volume":"85","author":"Matsuura","year":"2021","journal-title":"Circ. J."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/trf.16343","article-title":"A pilot study of the effect of rivaroxaban in sickle cell anemia","volume":"61","author":"Ataga","year":"2021","journal-title":"Transfusion"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.02.010","article-title":"Effect of combining aspirin and rivaroxaban on atherosclerosis in mice","volume":"345","author":"Grover","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.thromres.2022.09.024","article-title":"Inhibition of protein disulfide isomerase with PACMA-31 regulates monocyte tissue factor through transcriptional and posttranscriptional mechanisms","volume":"220","author":"Beckmann","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/jcp.30807","article-title":"Favorable effect of rivaroxaban against vascular dysfunction in diabetic mice by inhibiting NLRP3 inflammasome activation","volume":"237","author":"Li","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1055\/a-1759-9962","article-title":"CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage","volume":"122","author":"Roncal","year":"2022","journal-title":"Thromb. Haemost."},{"key":"ref_241","first-page":"111","article-title":"Dabigatran vs. low molecular weight heparin in preventing venous thromboembolism after elective hip and knee arthroplasty: Evaluation of selected clinical parameters","volume":"77","author":"Mrozik","year":"2012","journal-title":"Pol. Orthop. Traumatol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"118474","DOI":"10.1016\/j.lfs.2020.118474","article-title":"Influence of dabigatran on pro-inflammatory cytokines, growth factors and chemokines\u2014Slowing the vicious circle of coagulation and inflammation","volume":"262","author":"Paar","year":"2020","journal-title":"Life Sci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","article-title":"Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease","volume":"63","author":"Bogatkevich","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.114.218545","article-title":"Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice","volume":"351","author":"Kopec","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Singh, R., Singh, V., Ahmad, M.A., Pasricha, C., Kumari, P., Singh, T.G., Kaur, R., Mujwar, S., Wani, T.A., and Zargar, S. (2024). Unveiling the Role of PAR 1: A Crucial Link with Inflammation in Diabetic Subjects with COVID-19. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040454"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/bph.15587","article-title":"Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019","volume":"179","author":"Subramaniam","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"00379","DOI":"10.1183\/23120541.00379-2022","article-title":"Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19","volume":"8","author":"Tran","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/1535370220978372","article-title":"Protease-activated receptor 1 as a potential therapeutic target for COVID-19","volume":"246","author":"Rovai","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Borissoff, J.I., Otten, J.J., Heeneman, S., Leenders, P., van Oerle, R., and Soehnlein, O. (2013). Genetic and pharmacological modifications of thrombin formation in apolipoprotein e-deficient mice determine atherosclerosis severity and atherothrombosis onset in a neutrophil-dependent manner. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055784"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Tripathy, D., Sanchez, A., Yin, X., Luo, J., Martinez, J., and Grammas, P. (2013). Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front. Aging Neurosci., 5.","DOI":"10.3389\/fnagi.2013.00019"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5114\/aoms.2014.40742","article-title":"Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice","volume":"10","author":"Pingel","year":"2014","journal-title":"Arch. Med. Sci."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.2147\/DDDT.S86969","article-title":"Dabigatran etexilate retards the initiation and progression of atherosclerotic lesions and inhibits the expression of oncostatin M in apolipoprotein E-deficient mice","volume":"9","author":"Preusch","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"L768","DOI":"10.1152\/ajplung.00102.2015","article-title":"Effect of the oral thrombin inhibitor dabigatran on allergic lung inflammation induced by repeated house dust mite administration in mice","volume":"309","author":"Berkhout","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jneuroim.2016.05.018","article-title":"Differential effects on glial activation by a direct versus an indirect thrombin inhibitor","volume":"297","author":"Marangoni","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/1567202613666160517122605","article-title":"Dabigatran Etexilate Reduces Thrombin-Induced Inflammation and Thrombus Formation in Experimental Ischemic Stroke","volume":"13","author":"Dittmeier","year":"2016","journal-title":"Curr. Neurovasc. Res."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Shea, B.S., Probst, C.K., Brazee, P.L., Rotile, N.J., Blasi, F., Weinreb, P.H., Black, K.E., Sosnovik, D.E., Van Cott, E.M., and Violette, S.M. (2017). Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight, 2.","DOI":"10.1172\/jci.insight.86608"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1172\/JCI92744","article-title":"Thrombin promotes diet-induced obesity through fibrin-driven inflammation","volume":"127","author":"Kopec","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_258","first-page":"35","article-title":"Dabigatran aggravates topoisomerase I peptide-loaded dendritic cells-induced lung and skin fibrosis","volume":"35","author":"Mehta","year":"2017","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/aos.13630","article-title":"Dabigatran inhibits intravitreal thrombin activity","volume":"96","author":"Bastiaans","year":"2018","journal-title":"Acta Ophthalmol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/j.wneu.2019.02.139","article-title":"Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy","volume":"126","author":"Yilmaz","year":"2019","journal-title":"World Neurosurg."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.atherosclerosis.2019.06.897","article-title":"Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: Implications for atherosclerosis and adipose tissue inflammation","volume":"287","author":"Feldmann","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_262","doi-asserted-by":"crossref","unstructured":"Lerche, C.J., Christophersen, L.J., Goetze, J.P., Nielsen, P.R., Thomsen, K., Enevold, C., H\u00f8iby, N., Jensen, P.\u00d8., Bundgaard, H., and Moser, C. (2019). Adjunctive dabigatran therapy improves outcome of experimental left-sided Staphylococcus aureus endocarditis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215333"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/jth.14386","article-title":"Vascular protease-activated receptor 4 upregulation, increased platelet aggregation, and coronary lipid deposits induced by long-term dabigatran administration\u2014Results from a diabetes animal model","volume":"17","author":"Scridon","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_264","doi-asserted-by":"crossref","unstructured":"Iannucci, J., Johnson, S.L., Majchrzak, M., Barlock, B.J., Akhlaghi, F., and Seeram, N.P. (2020). Short-term treatment with dabigatran alters protein expression patterns in a late-stage tau-based Alzheimer\u2019s disease mouse model. Biochem. Biophys. Rep., 24.","DOI":"10.1016\/j.bbrep.2020.100862"},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Chen, R., Cao, X., Luo, W., Yang, H., Luo, X., and Yu, J. (2020). Dabigatran Suppresses PAR-1\/SphK\/S1P Activation of Astrocytes in Experimental Autoimmune Encephalomyelitis Model. Front. Mol. Neurosci., 13.","DOI":"10.3389\/fnmol.2020.00114"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"106632","DOI":"10.1016\/j.vph.2019.106632","article-title":"Thrombin inhibition by dabigatran attenuates endothelial dysfunction in diabetic mice","volume":"124","author":"Rahadian","year":"2020","journal-title":"Vascul Pharmacol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"173838","DOI":"10.1016\/j.ejphar.2020.173838","article-title":"A direct thrombin inhibitor, dabigatran etexilate protects from renal fibrosis by inhibiting protease activated receptor-1","volume":"893","author":"Saifi","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/lt.25929","article-title":"The Impact of Dabigatran Treatment on Sinusoidal Protection Against Hepatic Ischemia\/Reperfusion Injury in Mice","volume":"27","author":"Noguchi","year":"2021","journal-title":"Liver Transpl."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.7150\/thno.50182","article-title":"Dabigatran activates inflammation resolution by promoting fibrinogen-like protein 2 shedding and RvD5(n-3 DPA) production","volume":"11","author":"Lei","year":"2021","journal-title":"Theranostics"},{"key":"ref_270","first-page":"100014","article-title":"Dabigatran reduces thrombin-induced neuroinflammation and AD markers in vitro: Therapeutic relevance for Alzheimer\u2019s disease","volume":"2","author":"Bihaqi","year":"2021","journal-title":"Cereb. Circ. Cogn. Behav."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/ecco-jcc\/jjaa229","article-title":"Increased Mucosal Thrombin is Associated with Crohn\u2019s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation","volume":"15","author":"Motta","year":"2021","journal-title":"J. Crohns. Colitis."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Hemetsberger, R., Farhan, S., Lukovic, D., Zlabinger, K., Hajagos-Toth, J., Bota, J., Garcia-Garcia, H.M., Ay, C., Samaha, E., and Gaspar, R. (2021). Peri-interventional Triple Therapy With Dabigatran Improves Vasomotion and Promotes Endothelialization in Porcine Coronary Stenting Model. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.690476"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"834472","DOI":"10.3389\/fphar.2022.834472","article-title":"Direct Thrombin Inhibitor Dabigatran Compromises Pulmonary Endothelial Integrity in a Murine Model of Breast Cancer Metastasis to the Lungs; the Role of Platelets and Inflammation-Associated Haemostasis","volume":"13","author":"Smeda","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Youssef, M.E., Abdel-Reheim, M.A., Morsy, M.A., El-Daly, M., Atwa, G.M.K., Yahya, G., Cavalu, S., Saber, S., and Gaafar, A.G.A. (2022). Ameliorative Effect of Dabigatran on CFA-Induced Rheumatoid Arthritis via Modulating Kallikrein-Kinin System in Rats. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810297"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1172\/jci.insight.161145","article-title":"Preclinical testing of dabigatran in trypsin-dependent pancreatitis","volume":"7","author":"Pesei","year":"2022","journal-title":"JCI Insight"},{"key":"ref_276","doi-asserted-by":"crossref","unstructured":"Hemetsberger, R., Farhan, S., Lukovic, D., Zlabinger, K., Hajagos-Toth, J., and Bota, J. (2023). Peri-Interventional Triple Therapy with Dabigatran Modifies Vasomotion after Bare-Metal Stent Implantation in a Pig Coronary Artery Model. J. Pers. Med., 13.","DOI":"10.3390\/jpm13020280"},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2016.04.008","article-title":"Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran","volume":"142","author":"Ellinghaus","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40169-017-0179-9","article-title":"Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients","volume":"7","author":"Nakase","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5606\/tgkdc.dergisi.2022.22831","article-title":"Direct oral anticoagulant agents attenuate temporary aortic occlusion-induced renal oxidative and inflammatory responses in rats","volume":"30","author":"Durmaz","year":"2022","journal-title":"Turk. J. Thorac. Cardiovasc. Surg."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0042-1758855","article-title":"Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB\/c Mice","volume":"7","author":"Hiramoto","year":"2023","journal-title":"TH Open"},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Richards, G.A., Theron, A., Tintinger, G., and Anderson, R. (2018). The Effects of Dabigatran and Rivaroxaban on Markers of Polymorphonuclear Leukocyte Activation. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020046"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1007\/s00380-018-01324-7","article-title":"Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): Multicenter randomized study","volume":"34","author":"Kikuchi","year":"2019","journal-title":"Heart Vessel."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/1440-1681.13668","article-title":"Expression of anti and pro-inflammatory genes in human endothelial cells activated by 25-hydroxycholesterol: A comparison of rivaroxaban and dabigatran","volume":"49","author":"Pawlos","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_285","doi-asserted-by":"crossref","unstructured":"Yang, C., Wang, X., Guo, Y., Meng, X., Li, Y., Xia, C., Meng, L., Dong, M., and Wang, F. (2022). Beneficial Effect of Edoxaban on Preventing Atrial Fibrillation and Coagulation by Reducing Inflammation via HBG1\/HBD Biomarkers. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.904317"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0040-1715460","article-title":"The Anticoagulant and Nonanticoagulant Properties of Heparin","volume":"120","author":"Beurskens","year":"2020","journal-title":"Thromb. Haemost."},{"key":"ref_287","doi-asserted-by":"crossref","unstructured":"Hogwood, J., Pitchford, S., Mulloy, B., Page, C., and Gray, E. (2020). Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233644"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"117232","DOI":"10.1016\/j.carbpol.2020.117232","article-title":"Comprehensive Landscape of Heparin Therapy for COVID-19","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: Do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V82.11.3253.3253","article-title":"Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation","volume":"82","author":"Nelson","year":"1993","journal-title":"Blood"},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_292","doi-asserted-by":"crossref","unstructured":"Litov, L., Petkov, P., Rangelov, M., Ilieva, N., Lilkova, E., Todorova, N., Krachmarova, E., Malinova, K., Gospodinov, A., and Hristova, R. (2021). Molecular Mechanism of the Anti-Inflammatory Action of Heparin. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910730"},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/JBM.S285214","article-title":"Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study","volume":"12","author":"Cardillo","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1586\/erc.09.19","article-title":"Fondaparinux: An overview","volume":"7","author":"Nadar","year":"2009","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.4049\/jimmunol.0903678","article-title":"Molecular intercommunication between the complement and coagulation systems","volume":"185","author":"Amara","year":"2010","journal-title":"J. Immunol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/1755-5922.12018","article-title":"Factor Xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome","volume":"31","author":"Iba","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.5114\/amsad.2017.72533","article-title":"Non-hemorrhage-related adverse effects of rivaroxaban","volume":"2","author":"Christopoulou","year":"2017","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s10787-020-00693-8","article-title":"Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2\/STAT3 and MAPK phosphorylation pathways","volume":"28","author":"Helal","year":"2020","journal-title":"Inflammopharmacology"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.ade2574","article-title":"Evolutionary-scale prediction of atomic-level protein structure with a language model","volume":"379","author":"Lin","year":"2023","journal-title":"Science"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.add2187","article-title":"Robust deep learning-based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science"},{"key":"ref_302","doi-asserted-by":"crossref","unstructured":"Johnson, S.R., Fu, X., Viknander, S., Goldin, C., Monaco, S., Zelezniak, A., and Yang, K.K. (2024). Computational scoring and experimental evaluation of enzymes generated by neural networks. Nat. Biotechnol.","DOI":"10.1038\/s41587-024-02214-2"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt768","article-title":"Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes","volume":"21","author":"Martin","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_304","doi-asserted-by":"crossref","unstructured":"Petruzzella, A., Bruand, M., Santamaria-Martinez, A., Katanayeva, N., Reymond, L., Wehrle, S., Georgeon, S., Inel, D., van Dalen, F.J., and Viertl, D. (2024). Antibody-peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins. Nat. Chem. Biol.","DOI":"10.1038\/s41589-024-01627-z"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as Therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1038\/s41467-024-48211-6","article-title":"Aptameric hirudins as selective and reversible EXosite-ACTive site (EXACT) inhibitors","volume":"15","author":"Yu","year":"2024","journal-title":"Nat. Commun."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8727\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:25Z","timestamp":1760110465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/16\/8727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":306,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["ijms25168727"],"URL":"https:\/\/doi.org\/10.3390\/ijms25168727","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}